[PDF][PDF] Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment
S Bahadoram, M Davoodi, S Hassanzadeh… - G Ital Nefrol, 2022 - researchgate.net
Renal cell carcinoma (RCC) is the most common type of urogenital cancer. It has a mortality
rate of 30-40% and is more commonly seen in men than women. In addition to gender, other …
rate of 30-40% and is more commonly seen in men than women. In addition to gender, other …
Renal cell carcinoma
Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase …
Background A phase 2 trial showed improved progression-free survival for atezolizumab
plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who …
plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who …
Cuproptosis-associated lncRNA establishes new prognostic profile and predicts immunotherapy response in clear cell renal cell carcinoma
S Xu, D Liu, T Chang, X Wen, S Ma, G Sun… - Frontiers in …, 2022 - frontiersin.org
Background: Clear cell renal cell carcinoma (ccRCC) accounts for 80% of all kidney cancers
and has a poor prognosis. Recent studies have shown that copper-dependent, regulated …
and has a poor prognosis. Recent studies have shown that copper-dependent, regulated …
Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors
Messenger RNA encodes cellular function and phenotype. In the context of human cancer, it
defines the identities of malignant cells and the diversity of tumor tissue. We studied 72,501 …
defines the identities of malignant cells and the diversity of tumor tissue. We studied 72,501 …
Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME …
Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC)
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …
[HTML][HTML] Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir… - The lancet …, 2016 - thelancet.com
Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …
Renal cancer
U Capitanio, F Montorsi - The Lancet, 2016 - thelancet.com
The diagnosis and management of renal cell carcinoma have changed remarkably rapidly.
Although the incidence of renal cell carcinoma has been increasing, survival has improved …
Although the incidence of renal cell carcinoma has been increasing, survival has improved …
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Background Currently, metastatic renal cell carcinoma is treated with sequential single
agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their …
agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their …